Other Immune Pathways


Our pipeline includes a CTLA-4 antibody at the advanced pre-clinical stage and we promote additional immune-therapy antibodies which are at an earlier pre-clinical stage:

Immune Oncology

Clinical Indications:
Metastatic melanoma

Immune Oncology

A number of additional immune modulators were validated in vitro to have, upon blockade, a re-activation effect over the immune system in cancer treatment. However, to-date, the FDA has only approved blocking antibodies for immune-therapy for cancer for CTLA4 – for its ligands CD-80 and CD-86; for programmed cell death protein 1, (PD1 also known as CD279) – for its ligands PD-L1 and PD-L2; and for PD-L1 – for its receptor PD-1.

By leveraging a 3-dimensional antigen design approach, we plan to generate blocking antibodies to additional receptors and ligands of validated immune pathways. We will make an effort to generate blocking antibodies for pathways that have a synergetic benefit with the combination treatment of PD1 antibody and with CTLA-4 antibody treatment.

© Copyright 2015, Tikcro Ltd. | Legal - Terms of use | All rights reserved | Site by Imaginet